Blueprint Medicines (BPMC) Tops Q1 EPS by 50c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Blueprint Medicines (BPMC) Tops Q1 EPS by 50c

Blueprint Medicines Reports First Quarter 2023 Results

May 4, 2023 7:00 AM EDT

-- Achieved $39.1 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues and $63.3 million in total revenues in the first quarter of 2023 --

-- Raising 2023 AYVAKIT net product revenue guidance to $135 million to $145 million for advanced SM and GIST, excluding additional revenue associated with anticipated U.S. FDA approval for indolent SM --

-- FDA target action date for AYVAKIT supplemental new drug application for indolent SM is May 22, 2023 --  

CAMBRIDGE,... More